214 related articles for article (PubMed ID: 32330871)
1. Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles.
Chen CY; Tran DM; Cavedon A; Cai X; Rajendran R; Lyle MJ; Martini PGV; Miao CH
Mol Ther Nucleic Acids; 2020 Jun; 20():534-544. PubMed ID: 32330871
[TBL] [Abstract][Full Text] [Related]
2. Induction of long-term tolerance to a specific antigen using anti-CD3 lipid nanoparticles following gene therapy.
Chen CY; Vander Kooi A; Cavedon A; Cai X; Hoggatt J; Martini PGV; Miao CH
Mol Ther Nucleic Acids; 2023 Dec; 34():102043. PubMed ID: 37920545
[TBL] [Abstract][Full Text] [Related]
3. Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors.
Miao CH
Thromb J; 2016; 14(Suppl 1):41. PubMed ID: 27766066
[TBL] [Abstract][Full Text] [Related]
4. Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.
Wang X; Fu RY; Li C; Chen CY; Firrman J; Konkle BA; Zhang J; Li L; Xiao W; Poncz M; Miao CH
Blood Adv; 2020 Nov; 4(22):5722-5734. PubMed ID: 33216891
[TBL] [Abstract][Full Text] [Related]
5. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
6. [Molecular genetics of hemophilia A].
De Brasi CD; Slavutsky IR; Larripa IB
Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
[TBL] [Abstract][Full Text] [Related]
7. Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.
Russick J; Delignat S; Milanov P; Christophe O; Boros G; Denis CV; Lenting PJ; Kaveri SV; Lacroix-Desmazes S
Haematologica; 2020 Apr; 105(4):1129-1137. PubMed ID: 31289204
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size.
Di J; Du Z; Wu K; Jin S; Wang X; Li T; Xu Y
Pharm Res; 2022 Jan; 39(1):105-114. PubMed ID: 35080707
[TBL] [Abstract][Full Text] [Related]
9. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.
Pardi N; Tuyishime S; Muramatsu H; Kariko K; Mui BL; Tam YK; Madden TD; Hope MJ; Weissman D
J Control Release; 2015 Nov; 217():345-51. PubMed ID: 26264835
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
11. Lipid Nanoparticles Deliver the Therapeutic VEGFA mRNA In Vitro and In Vivo and Transform Extracellular Vesicles for Their Functional Extensions.
Nawaz M; Heydarkhan-Hagvall S; Tangruksa B; González-King Garibotti H; Jing Y; Maugeri M; Kohl F; Hultin L; Reyahi A; Camponeschi A; Kull B; Christoffersson J; Grimsholm O; Jennbacken K; Sundqvist M; Wiseman J; Bidar AW; Lindfors L; Synnergren J; Valadi H
Adv Sci (Weinh); 2023 Apr; 10(12):e2206187. PubMed ID: 36806740
[TBL] [Abstract][Full Text] [Related]
12. Novel Coagulation Factor VIII Gene Therapy in a Mouse Model of Hemophilia A by Lipid-Coated Fe
Kao YT; Chen YT; Fan HC; Tsai TC; Cheng SN; Lai PS; Chen JK; Chen CM
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572302
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice.
Song S; Lyle MJ; Noble-Vranish ML; Min-Tran DM; Harrang J; Xiao W; Unger EC; Miao CH
Mol Ther Nucleic Acids; 2022 Mar; 27():916-926. PubMed ID: 35141050
[TBL] [Abstract][Full Text] [Related]
14. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
[TBL] [Abstract][Full Text] [Related]
15. Systemic delivery of factor IX messenger RNA for protein replacement therapy.
Ramaswamy S; Tonnu N; Tachikawa K; Limphong P; Vega JB; Karmali PP; Chivukula P; Verma IM
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):E1941-E1950. PubMed ID: 28202722
[TBL] [Abstract][Full Text] [Related]
16. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
17. Lipid Nanoparticle Packaging Is an Effective and Nontoxic mRNA Delivery Platform in Embryonic Zebrafish.
Patton C; Farr GH; An D; Martini PGV; Maves L
Zebrafish; 2018 Jun; 15(3):217-227. PubMed ID: 29369745
[TBL] [Abstract][Full Text] [Related]
18. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles.
Evers MJW; Du W; Yang Q; Kooijmans SAA; Vink A; van Steenbergen M; Vader P; de Jager SCA; Fuchs SA; Mastrobattista E; Sluijter JPG; Lei Z; Schiffelers R
J Control Release; 2022 Mar; 343():207-216. PubMed ID: 35077739
[TBL] [Abstract][Full Text] [Related]
19. Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery.
Swingle KL; Billingsley MM; Bose SK; White B; Palanki R; Dave A; Patel SK; Gong N; Hamilton AG; Alameh MG; Weissman D; Peranteau WH; Mitchell MJ
J Control Release; 2022 Jan; 341():616-633. PubMed ID: 34742747
[TBL] [Abstract][Full Text] [Related]
20. Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs.
Jankowska KI; McGill J; Pezeshkpoor B; Oldenburg J; Atreya CD; Sauna ZE
Transfusion; 2020 Feb; 60(2):401-413. PubMed ID: 31785023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
